SCHEMBL9338708

SCHEMBL9338708

CC(C)c1cccc(C(=O)Nc2ccccc2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.62
RAB9A P51151 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
CASP3 P42574 1/20 0.62
SENP8 Q96LD8 1/20 0.62
SENP7 Q9BQF6 1/20 0.62
SENP6 Q9GZR1 1/20 0.62
HDAC1 Q13547 1/20 0.61
HDAC2 Q92769 1/20 0.61
HDAC8 Q9BY41 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
KCNK3 O14649 3/20 0.59
KCNK9 Q9NPC2 3/20 0.59
KAT6A Q92794 1/20 0.58
KMT2A Q03164 3/20 0.57
POLB P06746 2/20 0.57
FADS1 O60427 1/20 0.57
SIRT1 Q96EB6 1/20 0.57
MEN1 O00255 2/20 0.56
HTT P42858 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23844177 0.92 FADS1 (0.62) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL23844170 0.90 NPC1 (0.76) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL8283426 0.90 KCNK9 (0.69) NPC1RAB9ASMN1; SMN2KCNK3KCNK9
SCHEMBL29244995 0.88 NPC1 (0.66) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL30277642 0.86 NPC1 (0.62) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL30277489 0.86 MEN1 (0.71) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL12057348 0.86 NT5E (0.67) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL30277604 0.86 SMN1; SMN2 (0.66) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL12894454 0.85 KCNK9 (0.61) NPC1RAB9ASMN1; SMN2KCNK3KCNK9
SCHEMBL30277496 0.84 RAB9A (0.64) NPC1RAB9ASMN1; SMN2CASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4399198-A2 DUAL INHIBITOR OF HISTONE DEACETYLASE 6 AND HEAT SHOCK PROTEIN 90 Taipei Medical University (TW) 2024-07-17 EP claimed
WO-2023035005-A2 DUAL INHIBITOR OF HISTONE DEACETYLASE 6 AND HEAT SHOCK PROTEIN 90 TAIPEI MEDICAL UNIVERSITY (TW) 2023-03-09 WO claimed
EP-0318991-A2 Plant protection agents for control of fungi AGRO-KANESHO CO., LTD. (JP) 1989-06-07 EP claimed
EP-4399198-A2 DUAL INHIBITOR OF HISTONE DEACETYLASE 6 AND HEAT SHOCK PROTEIN 90 Taipei Medical University (TW) 2024-07-17 EP disclosed
WO-2024044757-A1 AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS Sanford Burnham Prebys Medical Discovery Institute (US) 2024-02-29 WO disclosed
WO-2023196601-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 WO disclosed
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 US disclosed
WO-2023035005-A2 DUAL INHIBITOR OF HISTONE DEACETYLASE 6 AND HEAT SHOCK PROTEIN 90 TAIPEI MEDICAL UNIVERSITY (TW) 2023-03-09 WO disclosed
WO-2022234965-A1 HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT 주식회사 보로노이 2022-11-10 WO disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
US-20220017762-A1 INK JET INK FOR FORMING AN INFRARED ABSORBING IMAGE, INFRARED ABSORBING IMAGE FORMING METHOD, AND RECORDED MATERIAL FUJIFILM CORPORATION (JP) 2022-01-20 US disclosed
US-20200369901-A1 DISPERSION, INK JET RECORDING METHOD, RECORDED MATERIAL, AND COMPOUND FUJIFILM CORPORATION (JP) 2020-11-26 US disclosed
US-20200347252-A1 INK COMPOSITION FOR INK JET PRINTING, IMAGE FORMING METHOD, AND RECORDED MATERIAL FUJIFILM CORPORATION (JP) 2020-11-05 US disclosed
US-20180071258-A1 ANTICANCER COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2018-03-15 US disclosed
EP-0318991-B1 Plant protection agents for control of fungi AGRO KANESHO CO LTD (JP) 1994-06-15 EP disclosed
US-4942178-A PLANT SAFTENING AGENTS, 3-ISOPROPYLBENZAMIDES AGRO-KANESHO CO., LTD. (JP) 1990-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC11 NPC1 2177/4885RAB9A 1958/4885SMN1; SMN2 498/4885
US-20180071258-A1 ANTICANCER COMPOUNDS RB1, MCL1, TP53 NPC1 890/4885RAB9A 375/4885SMN1; SMN2 2882/4885
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK NPC1 991/4885RAB9A 1568/4885SMN1; SMN2 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.